Gang of 7: Boehringer joins group of com­pa­nies tar­get­ed over drug dis­count pro­gram

Boehringer In­gel­heim on Mon­day joined a grow­ing list of bio­phar­ma com­pa­nies un­der pres­sure from the Biden ad­min­is­tra­tion’s HRSA af­ter re­strict­ing their own par­tic­i­pa­tion in a hos­pi­tal dis­count drug pro­gram be­cause of what they claim is an ex­ces­sive num­ber of con­tract phar­ma­cies.

Whether these vi­o­la­tions are vi­o­la­tions as HRSA con­tends will like­ly be de­cid­ed in court. Mean­while, HRSA has made its stance clear as it pre­vi­ous­ly sent iden­ti­cal let­ters to As­traZeneca, Eli Lil­ly, No­var­tis, No­vo Nordisk, Sanofi and Unit­ed Ther­a­peu­tics, ex­plain­ing how the ad­min­is­tra­tion has de­ter­mined their poli­cies plac­ing re­stric­tions on 340B pro­gram pric­ing re­lat­ed to con­tract hos­pi­tal phar­ma­cies are in di­rect vi­o­la­tion of the statute.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER